Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Tonix Pharmaceuticals

Drug Profile

Coronavirus vaccine - Tonix Pharmaceuticals

Alternative Names: COVID-19 vaccine - Tonix Pharmaceuticals; Live modified horsepox virus vaccine - Tonix Pharmaceuticals; TNX-1800

Latest Information Update: 22 May 2020

At a glance

  • Originator Tonix Pharmaceuticals Holding Corp
  • Class Recombinant proteins; Viral vaccines
  • Mechanism of Action Coronavirus spike glycoprotein modulators; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 12 May 2020 Tonix Pharmaceuticals has patent pending for technology related to TNX 1800 (Tonix Pharmaceuticals website, May 2020).
  • 12 May 2020 Tonix Pharmaceuticals announces intention to submit IND to regulatory bodies for COVID-2019 infections (Prevention)
  • 26 Feb 2020 Tonix Pharmaceuticals collaborates with Southern Research to develop modified horsepox virus vaccine for Coronavirus infections

Development Overview

Introduction

TNX 1800 is a live modified horsepox virus vaccine for percutaneous administration, being developed by Tonix Pharmaceuticals, in collaboration with Southern Research, for the prevention of COVID-2019 infections. The company is using its proprietary horsepox virus technology that developed vaccine engineered to express relevant protein antigens from the virus that causes COVID-19. The horsepox has the potential to serve as a vector for vaccines to protect against other infectious agents. TNX 1800 is designed to express the spike protein from the virus that causes COVID-19 (SARS-CoV-2) and to induce T cell response. The protein synthesis connected with a replicating live virus vaccine provides direct antigen presentation, which stimulates cellular immunity in addition to humoral immunity. Preclinical development is underway in the US.

Company Agreements

In February 2020, Tonix Pharmaceuticals entered into a research and development collaboration with Southern Research to develop TNX 1800 for the prevention of COVID-2019 infections, based on Tonix’s proprietary horsepox vaccine platform. Under the terms of the agreement, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from the virus that causes COVID-19. The collaboration seeks to leverage Tonix’s horsepox vaccine technology originally developed to protect against smallpox but has capabilities as a vector for other infectious diseases. [1]

Key Development Milestones

As of February 2020, modified horsepox virus vaccine was in pre-IND stage of the development [1] [2] .

Patent Information

As of May 2020, Tonix Pharmaceuticals has filed a provisional patent for technology related to TNX 1800 (Tonix Pharmaceuticals website, May 2020).

Drug Properties & Chemical Synopsis

  • Route of administration Topical
  • Formulation unspecified
  • Class Recombinant proteins, Viral vaccines
  • Target Coronavirus spike glycoprotein; T lymphocyte
  • Mechanism of Action Coronavirus spike glycoprotein modulators; Immunostimulants; T lymphocyte stimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical USA Topical / unspecified Tonix Pharmaceuticals Holding Corp 26 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Tonix Pharmaceuticals Holding Corp Originator USA
Tonix Pharmaceuticals Holding Corp Owner USA
Southern Research Collaborator England

Development History

Event Date Update Type Comment
12 May 2020 Patent Information Tonix Pharmaceuticals has patent pending for technology related to TNX 1800 (Tonix Pharmaceuticals website, May 2020). Updated 22 May 2020
12 May 2020 Regulatory Status Tonix Pharmaceuticals announces intention to submit IND to regulatory bodies for COVID-2019 infections (Prevention) Updated 22 May 2020
26 Feb 2020 Licensing Status Tonix Pharmaceuticals collaborates with Southern Research to develop modified horsepox virus vaccine for Coronavirus infections [1] Updated 06 Mar 2020
26 Feb 2020 Phase Change - Preclinical Preclinical trials in COVID-2019-infections (Prevention) in USA (Topical) before February 2020 [1] Updated 06 Mar 2020

References

  1. Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800).

    Media Release
  2. Investor Presentation: Tonix Pharmaceuticals. Internet-Doc 2020;.

    Available from: URL: https://content.equisolve.net/tonixpharma/media/cfe6777f777cbb421861e6b7727ebb85.pdf
Back to top